Navigation Links
Omeros Corporation Reports First Quarter 2013 Financial Results
Date:5/10/2013

SEATTLE, May 10, 2013 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the first quarter of 2013.

Financial ResultsTotal operating expenses for the quarter ended March 31, 2013 were $11.1 million compared to $9.6 million for the same period in 2012. The increase is primarily due to research and development expenses associated with advancing Omeros' MASP-2 program toward the clinic, employee costs and non-cash rent expense, and to selling, general and administrative expenses related to legal matters and Omeros' planned commercial launch of OMS302 in 2014.  These higher costs were partially offset by lower clinical trial expenses related to the completion of Phase 3 clinical trials for Omeros' OMS302 and OMS103HP programs in January 2013 and December 2012, respectively.  For the quarter ended March 31, 2013, Omeros reported a net loss of $10.5 million, or $0.40 per share, compared to a net loss of $8.9 million, or $0.40 per share, for the same period in 2012.

At March 31, 2013, Omeros had cash, cash equivalents and short-term investments of $13.3 million. On May 9, Omeros announced that it priced a public offering of 3,903,004 shares of its common stock at a price of $4.14 per share, a two percent premium over the closing price on May 8, 2013, for estimated net proceeds of $16.1 million. The offering is expected to close on or about May 14, 2013. The shares were offered and are expected to be sold to RA Capital Management and other investors in a registered direct offering conducted without an underwriter or placement agent. Omeros also did not use its at-the-market sales facility or its committed
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
2. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
3. Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
4. Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
5. Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
6. Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
7. Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
8. Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
9. Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
10. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
11. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Pfenex Inc. (NYSE MKT: PFNX) today announced ... of 8,333,333 shares of its common  stock at a price ... common stock was offered by Pfenex. In addition, Pfenex has ... 1,250,000 additional shares of common stock at the initial public ... the NYSE MKT under the symbol "PFNX." ...
(Date:7/29/2014)... , July 29, 2014  Landauer, Inc. (NYSE: ... and environmental radiation measurement and monitoring, outsourced medical physics ... financial results for the fiscal third quarter 2014 after ... The Company will host a conference call ... a.m. Central Time (10 a.m. Eastern Time). Investors may ...
(Date:7/29/2014)... 29, 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... targeting specific pathogens that cause serious infections and diseases, ... activity in the Company,s stock, the NYSE MKT (the ... usual practice. The Company stated that its policy is ... About Synthetic Biologics, Inc. Synthetic Biologics, Inc. ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity 2
... , MINNETONKA, Minn., Dec. 1 ... company specializing in clinical study management systems, today ... technology solution, has been certified by the Clinical ... the Operational Data Model (ODM) standard. This ...
... , CAMBRIDGE, Mass. and TOKYO, Dec. 1 Galenea ... further extension of their research and development collaboration through ... to seven years and brings the total committed funding ... working together since January 2005 with the goal of ...
Cached Medicine Technology:MedNet Solutions' ENLIGHTEN Receives CDISC ODM Certification 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 2Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration 3
(Date:7/29/2014)... Using quality improvement measures in eight of the 10 ... Group, researchers have found a way to reduce kidney ... , Currently, 7-15 percent of these patients who undergo ... kidney injury, which can result in death or rapid ... dialysis, says a study published in the July issue ...
(Date:7/29/2014)... Historically, Memorial Day kicks off a three ... throughout that time by picnics, barbecues and beach outings. ... the start of a period that will witness a ... 2012 nearly 1.000 people were killed in crashes involving ... Labor Day. , The summer's warmer weather, longer days ...
(Date:7/29/2014)... During his 37 years in dental practice, ... has had a steady stream of college students shadow him ... now gone on to dental school and some are now ... program helps college students find success. , For students interested ... the chance to see a realistic view of what goes ...
(Date:7/29/2014)... 29, 2014 A team of scientists, ... Ethell, PhD, has developed a blood test for Alzheimer’s ... the development of Alzheimer’s disease interventions, according to an ... a puzzle, and this study represents one of several ... the past couple of years,” Ethell said. , The ...
(Date:7/29/2014)... Just months after the recent announcement ... states, the exciting FX family does it again! Michael ... farmboy from Arkansas, is shocking the world with his ... to the masses. This time with their first ... Jamaica. This new office is scheduled to handle ...
Breaking Medicine News(10 mins):Health News:Reducing kidney injury using a quality improvement method 2Health News:Narconon New Life Retreat Launches New Alcohol Prevention Program 2Health News:Arthur Bruce Dental Helps College Students 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Atlanta Special FX Rapidly Expanding Just Opens First International Corporate Office in Jamaica 2
... Decreased muscle strength is associated with difficulty in ... kneeling (SCK) in older adults, according to an ... Physical Therapy (PTJ), the scientific journal ... researchers found that adults with SCK difficulty had ...
... They differ from each other in many ways, and they ... HIV to resist a host of weapons fired at ... emerging. One potential weapon is a small-molecule ... by attacking them through some feature common to an entire ...
... ... a Soho Seminar event that will help you transform the way employees engage inside and ... ... at the Soho Seminars event “Aligning the Corporate and Personal Brand,” hosted by Loyola ...
... effect on heart from androgen deprivation, official says ... with prostate cancer and the physicians who treat ... (ADT) commonly used against the malignancy might increase ... , "There is a substantial amount of data ...
... , PHILADELPHIA , ... GlaxoSmithKline plc will announce its full year financial results for the ... the announcement will be released to the London Stock Exchange at ... www.gsk.com . , Following the announcement, Andrew Witty , ...
... , , Rare, but serious, liver disorder ... 1 The U.S. Food and Drug Administration today announced ... has been reported in some HIV patients taking Videx/Videx EC ... is an antiretroviral medicine first approved by the FDA in ...
Cached Medicine News:Health News:Decreased muscle strength predicts functional impairments in older adults 2Health News:Decreased muscle strength predicts functional impairments in older adults 3Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 2Health News:Researchers find 'broad spectrum' antiviral that fights multitude of viruses 3Health News:7Summits to Present at Soho Seminars 'Alignment of Personal and Corporate Brands' 2Health News:Experts Issue Warning on Prostate Hormone Therapy 2Health News:Experts Issue Warning on Prostate Hormone Therapy 3Health News:GSK 2009 Financial Results Announcement and Teleconference Details 2Health News:FDA Announces Safety Risk Associated with HIV Drug 2
0.5mm 1X2 Teeth with 6mm Tying Platform; in Stainless Steel 125...
... necessary addition to any ... Reichert Trial Frame provides ... smooth controls for quick, ... design, high-quality materials, and ...
... CTS utilizes a small-cone design and ... a complete, shadow-free representation of the ... system that includes the topographer, PC, ... software enables quick and easy access ...
... AL500 incorporates all of the features you ... well as a color display, auto add-lock, ... design fits easily into your existing workspace, ... glare-free viewing at any angle.,Quick and accurate, ...
Medicine Products: